The economic burden of the opioid epidemic on states: the case of Medicaid.
- Authors
- Leslie, Douglas L; Ba, Djibril M; Agbese, Edeanya; Xing, Xueyi; Liu, Guodong
- Year
- 2019
- Journal
- The American journal of managed care
- PMID
- 31361426
The societal burden of opioid use disorder (OUD) is considerable and contributes to increased healthcare costs and overdose deaths. However, the burden is not well understood. The purpose of this analysis is to estimate the state Medicaid programs' costs for treating OUD and how these costs have changed over time. We used data from the Medicaid Analytic eXtract files from 17 states between 1999 and 2013 to examine the healthcare costs associated with OUD. Inpatient, outpatient, and prescription medication costs related to the treatment of OUD were included, as were excess costs for other healthcare services (eg, general medical care) for individuals with OUD relative to a comparison group of individuals without OUD matched on age, sex, and state. We then extrapolated our results to the entire US Medicaid population using population-based sample weights. All costs were adjusted for inflation and are reported in 2017 US dollars. During our study period, the number of patients who were diagnosed with OUD increased 378%, from 39,109 (0.21% of total Medicaid enrollment) in 1999 to 186,979 (0.60% of total Medicaid enrollment) in 2013 in our 17-state sample. Even after adjusting for inflation, total Medicaid costs associated with OUD more than tripled during this time, reaching more than $3 billion in 2013, from $919 million in 1999. Most of this growth was due to excess non-OUD treatment costs for patients with OUD, which increased 363% over the period; the rate of growth is triple the expenditures for OUD treatment services. When the results were extrapolated to the entire United States, the Medicaid costs associated with OUD increased from more than $2 billion in 1999 to more than $8 billion in 2013. The total cumulative costs that were associated with OUD for this extrapolated 50-state sample over a 15-year time period amounts to more than $72.4 billion. OUD imposes considerable financial burden on state Medicaid programs, and the burden is increasing over time.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. | 2022 | 36207451 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Characteristics and Economic Outcomes of Treated and Untreated Patients Diagnosed with Opioid Use Disorder. | Schmutz HW et al. | — | 2026 | → |
| Association Between Opioid Use Disorder and Healthcare Spending and Utilization in Emergency Surgical Patients: A Retrospective Analysis Using Commercial Claims. | Dixit AA et al. | — | 2025 | → |
| Continuation versus Interruption of Buprenorphine/Naloxone in Adult Veterans Undergoing Surgery: Examination of Postoperative Pain and Opioid Utilization in a National Retrospective Cohort Study. | Hitt JM et al. | — | 2025 | → |
| Opioid Use in Patients With Testicular Cancer: Patterns and Risk Factors. | Marthi S et al. | — | 2025 | → |
| Proactive Addiction Consultation for Hospitalized Patients With Opioid Use Disorder: A Pilot Study. | Karol DE et al. | — | 2025 | → |
| Healthcare expenditures for people with substance use disorders in drug courts compared to their peers in traditional courts. | Montgomery BW et al. | — | 2024 | → |
| Opioid Prescribing Patterns After Imposition of Setting-Specific Limits on Prescription Duration. | Allen LD et al. | — | 2024 | → |
| Preoperative opioid use is associated with worse two-year patient-reported outcomes after hand surgery: A retrospective cohort study. | Burt CI et al. | — | 2024 | → |
| Comparing professional communities: Opioid prescriber networks and Public Health Preparedness Districts. | Kaminski P et al. | — | 2023 | → |
| Noninvasive Bioelectronic Treatment of Postcesarean Pain: A Randomized Clinical Trial. | Grasch JL et al. | — | 2023 | → |
| Prevalence of Substance Abuse Among Trauma Patients in Rural West Virginia. | Mansoor K et al. | — | 2023 | → |
| Total cost of care associated with opioid use disorder treatment. | Toseef MU et al. | — | 2023 | → |
| Compliance With Opioid Disposal Following Opioid Disposal Education in Surgical Patients: A Systematic Review. | Dollar S et al. | — | 2022 | → |
| Conceptualizing and Measuring Abatement from the Opioid Epidemic: A Case Study from Pennsylvania. | Rhubart D et al. | — | 2022 | → |
| Health Status and Preventive Health Services Among Reproductive-Aged Women in Treatment for Opioid Use Disorder. | Short VL et al. | — | 2022 | → |
| Machine Learning to Predict Successful Opioid Dose Reduction or Stabilization After Spinal Cord Stimulation. | Adil SM et al. | — | 2022 | → |
| Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. | Gaddis N et al. | — | 2022 | → |
| Opioid Use Disorder Among Ohio's Medicaid Population: Prevalence Estimates From 19 Counties Using a Multiplier Method. | Doogan NJ et al. | — | 2022 | → |
| Pain pathways and potential new targets for pain relief. | Wang M et al. | — | 2022 | → |
| Patient and medication-related factors associated with opioid use disorder after inpatient opioid administration. | Swart ECS et al. | — | 2022 | → |
| The association of prescription opioid use with suicide attempts: An analysis of statewide medical claims data. | Luo C et al. | — | 2022 | → |
| Trends in opioid use following balloon kyphoplasty or vertebroplasty for the treatment of vertebral compression fractures. | Ni W et al. | — | 2022 | → |
| Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research. | Patton T et al. | — | 2022 | → |
| Advances in 3D neuronal microphysiological systems: towards a functional nervous system on a chip. | Anderson WA et al. | — | 2021 | → |
| A machine learning based two-stage clinical decision support system for predicting patients' discontinuation from opioid use disorder treatment: retrospective observational study. | Hasan MM et al. | — | 2021 | → |
| Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. | Kohan L et al. | — | 2021 | → |
| Data Needs in Opioid Systems Modeling: Challenges and Future Directions. | Jalali MS et al. | — | 2021 | → |
| Infectious Complications in Injection Drug Use. | Knodle R et al. | — | 2021 | → |
| Plan Type and Opioid Prescriptions for Children in Medicaid. | Banks J et al. | — | 2021 | → |
| Prevalence of Problematic Use of Opioids in Patients with Chronic Noncancer Pain: A Systematic Review with Meta-analysis. | Jantarada C et al. | — | 2021 | → |
| "Stories of starting": Understanding the complex contexts of opioid misuse initiation. | Spencer NE et al. | — | 2021 | → |
| The Financial Burden of Opioid-Related Abuse among Surgical and Non-Surgical Patients in Florida: A Longitudinal Study. | Xu J et al. | — | 2021 | → |
| Trends in national opioid prescribing for dental procedures among patients enrolled in Medicaid. | Okunev I et al. | — | 2021 | → |
| Cannabis as a Gateway Drug for Opioid Use Disorder. | Williams AR | — | 2020 | → |
| Factors associated with the prescribing of high-dose opioids in primary care: a systematic review and meta-analysis. | Richards GC et al. | — | 2020 | → |
| Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. | Aldridge AP et al. | — | 2020 | → |
| Incidence rates of and risk factors for opioid overdose in new users of prescription opioids among US Medicaid enrollees: A cohort study. | Nam YH et al. | — | 2020 | → |
| Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. | Cochran G et al. | — | 2020 | → |
| Opioid-Related Emergency Department Visits and Access to Health Care--An Opportunity for Treatment Engagement. | Ali MM | — | 2020 | → |
| The cost of opioid use disorder and the value of aversion. | Murphy SM | — | 2020 | → |
| The state of the science in opioid policy research. | Schuler MS et al. | — | 2020 | → |
| Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders. | O'Brien P et al. | — | 2020 | → |
| Considering the child welfare system burden from opioid misuse: research priorities for estimating public costs. | Crowley DM et al. | — | 2019 | → |